Covista Inc.

NYSE:CVSA Rapport sur les actions

Capitalisation boursière : US$4.5b

Covista Croissance future

Future contrôle des critères 1/6

Covista devrait augmenter ses bénéfices et ses revenus de 12.1% et de 7% par an respectivement, tandis que le BPA devrait croître de croître de 14.4% par an.

Informations clés

12.1%

Taux de croissance des bénéfices

14.41%

Taux de croissance du BPA

Consumer Services croissance des bénéfices13.0%
Taux de croissance des recettes7.0%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour26 Jun 2026

Mises à jour récentes de la croissance future

Recent updates

Mise à jour du récit Jun 26

CVSA: Student Enrollment Momentum And Campus Expansion Will Support Future Upside

The analyst price target for Covista has increased from $130 to $140, with analysts citing updated assumptions on revenue growth, profit margins, and future P/E as the key reasons for the change. What’s in the News for Covista Covista raised its fiscal 2026 revenue guidance to a range of approximately US$1.93b to US$1.945b, compared with the prior range of US$1.9b to US$1.94b, with guidance implying about 8% to 9% year-over-year growth.
Seeking Alpha Jun 03

Covista: Healthcare Education Growth At A Fair Price

Summary Covista (CVSA) is rated Hold, reflecting strong healthcare education positioning but a valuation that prices in much of its growth story. CVSA's enrollment growth, AI-enabled offerings, and robust cash flow support its strategic pivot, yet it trades near peer medians on key valuation multiples. Regulatory risks tied to Title IV funding and ongoing lawsuits warrant a risk premium, tempering the case for aggressive buying at current levels. Peers like PRDO offer lower multiples and stronger cash conversion, while LOPE commands a premium for a cleaner balance sheet and superior cash generation. Read the full article on Seeking Alpha
Nouveau récit Apr 22

Health Care Workforce Shortages Will Pressure Capacity Expansion Yet Support Long Term Potential

Catalysts About Covista Covista is a health care education provider focused on training nurses, physicians, veterinarians and behavioral health professionals at scale. What are the underlying business or industry changes driving this perspective?
Nouveau récit Apr 08

Health Care Workforce Shortages And Digital Learning Will Support This Bullish Long Term Thesis

Catalysts About Covista Covista provides higher education programs focused on health care and related professional fields. What are the underlying business or industry changes driving this perspective?
Nouveau récit Mar 24

Health Care Workforce Shortages And Flexible Learning Will Support Stronger Long Term Outcomes

Catalysts About Covista Covista focuses on large scale health care education programs serving nursing, medical, veterinary and allied health students across the United States. What are the underlying business or industry changes driving this perspective?
Article d’analyse Sep 27

With EPS Growth And More, Adtalem Global Education (NYSE:ATGE) Makes An Interesting Case

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Article d’analyse Aug 07

Adtalem Global Education (NYSE:ATGE) Has A Pretty Healthy Balance Sheet

NYSE:ATGE 1 Year Share Price vs Fair Value Explore Adtalem Global Education's Fair Values from the Community and select...
Article d’analyse Jul 07

An Intrinsic Calculation For Adtalem Global Education Inc. (NYSE:ATGE) Suggests It's 44% Undervalued

Key Insights Adtalem Global Education's estimated fair value is US$221 based on 2 Stage Free Cash Flow to Equity...
Article d’analyse May 13

There's Reason For Concern Over Adtalem Global Education Inc.'s (NYSE:ATGE) Massive 27% Price Jump

Adtalem Global Education Inc. ( NYSE:ATGE ) shareholders have had their patience rewarded with a 27% share price jump...
Article d’analyse May 07

If EPS Growth Is Important To You, Adtalem Global Education (NYSE:ATGE) Presents An Opportunity

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Article d’analyse Apr 24

Is Adtalem Global Education (NYSE:ATGE) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Article d’analyse Mar 25

Adtalem Global Education Inc. (NYSE:ATGE) Shares Could Be 48% Below Their Intrinsic Value Estimate

Key Insights Adtalem Global Education's estimated fair value is US$198 based on 2 Stage Free Cash Flow to Equity...
Article d’analyse Mar 11

Subdued Growth No Barrier To Adtalem Global Education Inc.'s (NYSE:ATGE) Price

With a median price-to-earnings (or "P/E") ratio of close to 17x in the United States, you could be forgiven for...
Article d’analyse Feb 24

Is There Now An Opportunity In Adtalem Global Education Inc. (NYSE:ATGE)?

Adtalem Global Education Inc. ( NYSE:ATGE ), is not the largest company out there, but it saw a decent share price...
Seeking Alpha Feb 21

Adtalem Global Education: Surging On Registered Nurse Shortage

Summary Adtalem Global Education Inc.'s financial performance has surged with an underlying nationwide shortage of Registered Nurses and in mental health professionals. A shortage is expected to persist — Adtalem still looks to benefit from secular trends in an aging population, while the long-term performance depends on universities' ability to expand capacity. ATGE stock's surge already reflects a good mid-term earnings performance, making long-term growth required for significant returns. I estimate a fair value of $109.5. Read the full article on Seeking Alpha
Article d’analyse Jan 21

With EPS Growth And More, Adtalem Global Education (NYSE:ATGE) Makes An Interesting Case

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Article d’analyse Dec 19

These 4 Measures Indicate That Adtalem Global Education (NYSE:ATGE) Is Using Debt Reasonably Well

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha Dec 17

Adtalem Global Education Still Offers Competitive PEG Ratio And Substantial Share Buybacks

Summary The company has shown significant financial progress with improving EBIT and profit margins, indicating efficient cost management. Current valuation metrics suggest the company is rather cheaply priced, despite the good run in 2024. The future outlook remains positive, but investors should be aware of potential risks, such as the debt or future competitive threats from robotics. Read the full article on Seeking Alpha
Article d’analyse Nov 26

Adtalem Global Education Inc.'s (NYSE:ATGE) Shares Climb 27% But Its Business Is Yet to Catch Up

Adtalem Global Education Inc. ( NYSE:ATGE ) shareholders would be excited to see that the share price has had a great...
Article d’analyse Oct 31

Should You Think About Buying Adtalem Global Education Inc. (NYSE:ATGE) Now?

Adtalem Global Education Inc. ( NYSE:ATGE ), is not the largest company out there, but it led the NYSE gainers with a...
Article d’analyse Oct 16

Should You Be Adding Adtalem Global Education (NYSE:ATGE) To Your Watchlist Today?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Seeking Alpha Oct 04

Adtalem Global Education Faces Problems But Is Growing Steadily

Summary Adtalem Global Education focuses on medical and veterinary education, showing solid profitability and potential growth in a booming healthcare industry. Despite a current ratio below 1.0, ATGE maintains a reasonable price/book ratio and generates significant operating cash flow, indicating financial stability. Risks include reliance on government financial aid, maintaining accreditation, and ensuring student placements in healthcare jobs, which are crucial for sustaining reputation and revenue. With projected revenue growth and a forward P/E ratio of 13.12, Adtalem Global is a cautious buy, offering portfolio diversity in a growing sector. Read the full article on Seeking Alpha
Article d’analyse Sep 16

Adtalem Global Education (NYSE:ATGE) Seems To Use Debt Quite Sensibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Article d’analyse Aug 29

Adtalem Global Education Inc.'s (NYSE:ATGE) Price In Tune With Earnings

With a price-to-earnings (or "P/E") ratio of 20.7x Adtalem Global Education Inc. ( NYSE:ATGE ) may be sending bearish...
Article d’analyse Aug 14

We Think Adtalem Global Education's (NYSE:ATGE) Robust Earnings Are Conservative

Even though Adtalem Global Education Inc.'s ( NYSE:ATGE ) recent earnings release was robust, the market didn't seem to...
Article d’analyse Jul 28

Should You Think About Buying Adtalem Global Education Inc. (NYSE:ATGE) Now?

While Adtalem Global Education Inc. ( NYSE:ATGE ) might not have the largest market cap around , it led the NYSE...
Seeking Alpha Jul 27

Adtalem Global Education: Still Undervalued After The Latest Rally

Summary Adtalem Global Education is set to report earnings on August 6th. The company specializes in healthcare education, with Chamberlain and Walden Universities under its wing, showing revenue growth post Walden acquisition. Financials show decent margins, but efficiency metrics trending down, with potential for top-line growth and margin expansion in the future. Read the full article on Seeking Alpha
Article d’analyse Jul 12

Does Adtalem Global Education (NYSE:ATGE) Deserve A Spot On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Article d’analyse Jun 14

Adtalem Global Education (NYSE:ATGE) Has A Pretty Healthy Balance Sheet

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Prévisions de croissance des bénéfices et des revenus

NYSE:CVSA - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
6/30/20292,4133594185231
6/30/20282,2323243434442
6/30/20272,0692972973984
6/30/20261,9392462843584
3/31/20261,910250336406N/A
12/31/20251,889254368428N/A
9/30/20251,833247323379N/A
6/30/20251,788233288338N/A
3/31/20251,741229291338N/A
12/31/20241,688204234284N/A
9/30/20241,633172241290N/A
6/30/20241,585138247296N/A
3/31/20241,539111239278N/A
12/31/20231,496122196232N/A
9/30/20231,465108165196N/A
6/30/20231,451102166192N/A
3/31/20231,4477980108N/A
12/31/20221,442352551N/A
9/30/20221,447473161N/A
6/30/20221,382-36-2011N/A
3/31/20221,245-3566100N/A
12/31/20211,111-1595130N/A
9/30/2021977-26121153N/A
6/30/202189963152192N/A
3/31/2021943139106146N/A
12/31/2020984269141185N/A
9/30/20201,01624692140N/A
6/30/202086622068108N/A
3/31/20201,057208138182N/A
12/31/20191,04489N/A168N/A
9/30/20191,032130N/A174N/A
6/30/20191,014107N/A205N/A
3/31/20191,069169N/A184N/A
12/31/20181,121177N/A212N/A
9/30/20181,17584N/A227N/A
6/30/201896068N/A239N/A
3/31/20181,12467N/A244N/A
12/31/20171,14661N/A239N/A
9/30/20171,172119N/A222N/A
6/30/20171,208120N/A231N/A
3/31/20171,46759N/A178N/A
12/31/20161,60975N/A193N/A
9/30/20161,73117N/A210N/A
6/30/20161,080125N/A231N/A
3/31/20161,84537N/A213N/A
12/31/20151,86126N/A187N/A
9/30/20151,889119N/A179N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de CVSA ( 12.1% par an) est supérieure au taux d'épargne ( 3.5% ).

Bénéfices vs marché: Les bénéfices de CVSA ( 12.1% par an) devraient croître plus lentement que le marché US ( 18.3% par an).

Croissance élevée des bénéfices: Les bénéfices de CVSA devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CVSA ( 7% par an) devrait croître plus lentement que le marché de US ( 13% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CVSA ( 7% par an) devrait croître plus lentement que 20% par an.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CVSA devrait être élevé dans 3 ans


Découvrir les entreprises en croissance

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/07/12 01:06
Cours de l'action en fin de journée2026/07/10 00:00
Les revenus2026/03/31
Revenus annuels2025/06/30

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Covista Inc. est couverte par 24 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Gary BisbeeBarclays
Gary PrestopinoBarrington Research Associates, Inc.
Alexander ParisBarrington Research Associates, Inc.